ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,336Medicare Part D Prescriptions Filled, Including Refills

Rank: 59 out of 1155

$480K Total Retail Price of All Prescriptions

Rank: 56 out of 1155

613 Patients Receiving at Least One Drug in Part D
84%Patients 65 Years and Older
34% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oregon
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 613 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

16% of this provider’s 613 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

2% of this provider’s 7,692 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $50 among peers.

Prescriptions per Patient

15 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oregon
LISINOPRIL 482 407 1 1
LEVOTHYROXINE SODIUM 422 371 2 2
HYDROCODONE-ACETAMINOPHEN 354 269 S3 3 4
SIMVASTATIN 266 244 4 3
TRAZODONE HCL 257 190 5 22
METFORMIN HCL 246 214 6 7
AMLODIPINE BESYLATE 220 196 7 6
OMEPRAZOLE 215 183 8 5
METOPROLOL TARTRATE 206 182 9 14
ALENDRONATE SODIUM 203 203 10 25
PRAVASTATIN SODIUM 188 124 11 20
ATENOLOL 186 162 12 10
SERTRALINE HCL 174 139 13 24
HYDROCHLOROTHIAZIDE 164 141 14 9
FUROSEMIDE 156 127 15 8
LOVASTATIN 134 106 16 13
GABAPENTIN 124 105 17 15
WARFARIN SODIUM 120 115 18 11
ZOLPIDEM TARTRATE 116 101 19 21
LOSARTAN POTASSIUM 112 109 20 18
PAROXETINE HCL 94 79 21 48
CITALOPRAM HBR 92 70 22 19
LANTUS 89 55 23 39
ATORVASTATIN CALCIUM 85 82 24 12
OXYBUTYNIN CHLORIDE 78 60 25 71
RISPERIDONE 77 77 26 73
FLUTICASONE PROPIONATE 74 61 27 37
DONEPEZIL HCL 73 73 28 41
PROAIR HFA 71 42 29 31
METOPROLOL SUCCINATE 70 70 30 17
OXYCODONE HCL 70 53 S2 30 23
GLIPIZIDE 69 47 32 44
TRAMADOL HCL 69 64 32 32
POTASSIUM CHLORIDE 66 47 34 16
NOVOLOG 64 39 35 135
SPIRONOLACTONE 63 46 36 55
NAMENDA 63 63 36 67
PANTOPRAZOLE SODIUM 63 45 36 47
LYRICA 62 30 39 146
CRESTOR 56 56 40 34
ACETAMINOPHEN-CODEINE 56 56 S3 40 101
INSULIN SYRINGE 54 49 42 90
ADVAIR DISKUS 53 30 43 35
ESTRADIOL 50 43 R 44 60
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 23, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.